PuraPharm Wins Corporate Achievement Award at Outstanding Import & Export Enterprise Awards 2016

PuraPharm Corporation Limited (“PuraPharm” or the “Group”, stock code: 1498), a leading Hong Kong-based Chinese medicine company specialising in the research and development, production and sale of Concentrated Chinese Medicine Granules (“CCMG”) products under the “Nong’s^® (農本方^®)” brand. The Group is delighted to announce that it has been awarded “Corporate Achievement Award” at the Outstanding Import and Export Enterprise Awards 2016 yesterday. The award is certainly an acknowledgement of the Group’s outstanding performance in business development and market expansion, and an affirmation to the society-wide and industry-wide recognitions of the Group’s products and achievements.

Organised by the Hong Kong Chinese Importers’ & Exporters’ Association, the award aims to promote and recognise the tremendous efforts and contributions made by import and export enterprises for the betterment of Hong Kong’s economic development. Since its establishment, the association has been committed to promoting trade between local enterprises and other businesses overseas through organising activities such as economic forums and seminars in order to share the latest business information to industry players.

Mr. Abraham Chan, Founder, Chairman, Chief Executive Officer and Executive Director of PuraPharm, said, “We are very honoured and inspired to have received the Corporate Achievement Award, owed very much to the contributions of our team over the years. As Hong Kong’s largest supplier of CCMG products, we are committed to achieving our goal of modernising Chinese medicine. To strengthen the Group’s competitive advantages, we have been developing and introducing new products and also actively enhancing PuraPharm and Nong’s^® brand recognition in China and overseas. The rapid expansion of Nong’s^® clinic is also a proof of our success. In addition to opening more Nong’s^® Chinese medicine clinics in Hong Kong, we will also replicate the successful clinic business model in China and overseas markets. We plan to open our first Nong’s^® Chinese medicine clinic in Toronto, Canada and our first Nong’s^® Chinese medicine clinic in Nanning, Guangxi Zhuang Autonomous Region within this year, along with the number of clinics in Hong Kong reaching the significant benchmark of 50 by end of this year.”

Mr. Chan added, “On top of expanding the clinic network, PuraPharm has broadened the market coverage in order to boost its sales network and deepen market penetration, enabling the distribution of CCMG products to more cities and increase its market share. The Group has also strengthened its supply chain management to ensure it has a solid foundation to support its long term business growth and development. With the experienced management team and sophisticated product development capabilities, we will continue to capitalise on the huge demand for Chinese medicine and the business opportunities brought by CCMG products, and will continue to push towards our goal of modernising Chinese medicine and putting it on the map of the world.”

The details of Outstanding Import & Export Enterprise Award 2016 can be viewed at:
http://hkciea.org.hk/activity_detail.php?id_activity=233&lang=en